Two major health systems will not administer controversial Aduhelm
Jul 15, 2021
Individual doctors can prescribe Aduhelm, but patients would have to go elsewhere to receive the drug via infusion.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
Medicare may rethink premium hike for pricey Alzheimer’s drug
Jan 10, 2022
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Medicare mulls coverage for controversial drug for Alzheimer’s disease
Jul 13, 2021
CMS says a final decision on coverage is not likely until next spring.
House committees to investigate new Alzheimer’s disease drug approval
Jul 01, 2021
The FDA approved aducanumab earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness.
Pricey Alzheimer drug drives spike in Medicare B premium: Officials
Nov 15, 2021
New premium will be $170.10 a month, and the $21.60 boost is the biggest increase ever in dollar amount, but not in percentage terms
Lilly to seek FDA approval for new drug for Alzheimer’s disease
Jun 25, 2021
Donanemab already has received a ‘breakthrough therapy’ designation from the FDA.
Medicare will only cover Aduhelm for patients in clinical trials
Apr 08, 2022
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.